Skip to content
Screener

Enliven Therapeutics ELVN Q4 2025 Annual earnings

Reported March 3, 2026 · Before market open

EPS-$0.48Miss by $0.06
Revenue estimate$12.5K
EPS estimate-$0.42

Next report

Date not yet announced

Financials

Q4 2025

Income statement

See full
Operating income-$34.3M-27.5%
Net income-$29.7M-28.0%
EPS (diluted)-$0.48-4.3%

Balance sheet

See full
Cash & equivalents$98.9M-20.3%
Total debt$399.0K—
Total equity$459.6M+48.3%
Total assets$476.2M+46.2%

Cash flow

See full
Operating cash flow-$15.8M+7.9%
Free cash flow-$15.8M+7.9%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$913.95M-16.9%
Enterprise value$815.45M—

Returns & leverage

See full
Return on equity-27%-3.7pp
Debt / equity0×—
Current ratio28.7×+8.7×

FAQ

When did Enliven Therapeutics report Q4 2025 earnings?
Enliven Therapeutics (ELVN) reported Q4 2025 earnings on March 3, 2026 before market open.
What were Enliven Therapeutics's Q4 2025 revenue and EPS?
Enliven Therapeutics reported eps of $-0.48 for Q4 2025.
Did Enliven Therapeutics beat estimates in Q4 2025?
EPS missed the consensus estimate of $-0.42 by $0.06.
How did Enliven Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 4.3% from $-0.46.
Where can I find Enliven Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-088195) and the 10-K periodic report (0001193125-26-088232) directly on SEC EDGAR. The filing index links above go to sec.gov.